After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...

Usually described as a splitting or multiple personality disorder, the concept of schizophrenia is not entirely but rather a ...

The vast majority of people in psychosis aren’t violent—but Cohen Miles-Rath was. Here's what that can teach us about mental ...

Schizophrenia is a serious mental disorder that affects around 1% of the world's population. Researchers have identified a deficit in contrast perception in people with schizophrenia. According to a ...

As per the Brain and Behavior Research Foundation, it combines two compounds called xanomeline and trospium chloride. This is ...

AVXL stock soars 95% in three months on positive updates from the development programs of its two clinical candidates, blarcamesine and ANAVEX 3-71.

Peptide antigen-associated IgG levels were significantly lower in drug-naïve patients with first episode psychosis compared to control individuals.

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Xanomeline and trospium chloride (KarXT), a novel M1/M4 muscarinic receptor agonist, significantly improves cognitive ...

There are as yet no effective drugs for negative symptoms like social withdrawal and lack of motivation. Read more at ...

At the Institute of Mental Health (IMH), almost 60 per cent to 70 per cent of patients with schizophrenia make a good ...

Boehringer Ingelheim announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia ...